Stalicla Seals Deal To Advance Novartis Drug For Cocaine Misuse
Seeking The Right Indication For Mavoglurant
The biotech has persuaded its fellow Swiss firm that it can advance mavoglurant, a Novartis drug that has failed in Parkinson’s and Fragile X syndrome, for cocaine use and neurodevelopmental disorders.
